Compass Pathways/$CMPS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ticker
$CMPS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
166
ISIN
US20451W1018
Website
Compass Pathways Metrics
BasicAdvanced
$449M
-
-$1.94
2.28
-
Price and volume
Market cap
$449M
Beta
2.28
52-week high
$8.54
52-week low
$2.49
Average daily volume
1.4M
Financial strength
Current ratio
10.183
Quick ratio
8.671
Long term debt to equity
11.159
Total debt to equity
16.388
Interest coverage (TTM)
-36.14%
Profitability
EBITDA (TTM)
-162.595
Effective tax rate (TTM)
-1.27%
Management effectiveness
Return on assets (TTM)
-32.40%
Return on equity (TTM)
-60.62%
Valuation
Price to book
2.28
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-2.457
Free cash flow yield (TTM)
-40.70%
Free cash flow per share (TTM)
-195.34%
Growth
Earnings per share change (TTM)
-15.40%
3-year earnings per share growth (CAGR)
0.08%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Bulls say / Bears say
Analysts have assigned COMPASS Pathways an average 'Buy' rating with a consensus target price of $21.83, indicating potential upside from its current trading price. (Defense World)
The company maintains a strong cash position, with liquid assets exceeding short-term obligations, providing financial stability to support ongoing research and development. (Investing.com)
Institutional investors, such as Renaissance Technologies LLC, have increased their holdings in COMPASS Pathways, reflecting confidence in the company's future prospects. (ETF Daily News)
The company reported an operating loss of approximately $124.04 million over the last twelve months, indicating a high cash burn rate that may necessitate additional financing. (Investing.com)
Short interest in COMPASS Pathways increased by 21.7% in February, suggesting that a growing number of investors are betting against the stock. (Techdows News)
A company director sold over $700,000 worth of shares, which could be perceived as a lack of confidence in the company's near-term performance. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
Business Wire·1 month ago
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
Business Wire·1 month ago
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $449M as of June 20, 2025.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of June 20, 2025.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.